Pfizer Inc. will host a conference call with investment analysts on August 4, 2026, to provide an update on its Second Quarter 2026 performance. The webcast is scheduled to begin at 10:00 a.m. EDT. The company will release its Second Quarter 2026 Performance Report that morning.

Accessing the Webcast

Investors and the public can access the live webcast and the accompanying report through Pfizer's investor relations website. Registration information is available now, and participants are advised to register in advance.

Dial-in Information

Participants can also join the conference call via telephone. The company has provided specific numbers for callers within and outside the United States and Canada.

Replay Availability

A transcript and replay of the webcast will be posted on Pfizer's investor website within 24 hours after the conclusion of the live call. The content will remain accessible for at least 90 days.

Pfizer Inc. shares fell 0.91% to $24.98 on Monday as investors digest a leadership transition in the finance seat. Chief Financial Officer Dave Denton is set to step down on August 15 to pursue a role in the consumer goods industry, while Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, will become Interim Chief Financial Officer effective August 16. The stock is under pressure, trading below key moving averages, as the company initiates a search for a permanent successor.

Chief Executive Officer Albert Bourla thanked Denton for his stewardship during major transactions, including the Seagen, Biohaven, and Metsera deals, and expressed confidence in Guegan's ability to lead the finance organization. Guegan brings over two decades of experience at Pfizer and played a key role in the financial integration of Seagen in 2024. Pfizer is leaning on continuity to ensure a smooth handoff, even as the stock trades in a fragile technical posture.

Technical Analysis

Pfizer is stuck under key moving averages, keeping rallies looking more like rebounds than breakouts. The stock sits 3.1% under the 20-day simple moving average ($25.80), 4.6% under the 50-day simple moving average ($26.20), 6.2% under the 100-day simple moving average ($26.66), and 3.4% under the 200-day simple moving average ($25.88). This alignment indicates that recent rebounds have struggled to push through overhead supply.

The Relative Strength Index (RSI) is holding at 48.91, reflecting neutral momentum. The moving-average structure is mixed: the 20-day average is below the 50-day average (a bearish short-term crossover), but the 50-day average remains above the 200-day average after a golden cross formed in October 2025.

Sector and Peer Comparison

Pfizer is underperforming its Healthcare peer group, down 0.32% versus a 0.13% gain for the sector. This weakness reads as more stock-specific than sector-driven, as Healthcare is currently a top-performing group. Merck’s Capvaxive label expansion provides a benchmark for Pfizer, as pneumococcal vaccines are a key competitive arena for big pharma immunization franchises.

Business Overview and Outlook

Pfizer is one of the world’s largest pharmaceutical firms, with annual sales of roughly $60 billion, leaning heavily on prescription drugs and vaccines. Key products include the pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. International markets make up about 40% of total sales. The company must also navigate shifting demand narratives in obesity care, where GLP-1 users are consuming up to 21% fewer calories, shaping how investors think about pharma winners and losers.